Based on the aggregated intelligence of 145,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, surgical implant specialist RTI Biologics (NASDAQ:RTIX) has earned a respected four-star ranking.

With that in mind, let's take a closer look at RTI Biologics' business and see what CAPS investors are saying about the stock right now.

RTI Biologics facts

Headquarters (Founded)

Alachua, Fla. (1997)

Market Cap

$170 million


Health-care equipment and supplies

Trailing-12-Month Revenue

$160 million


CEO Brian Hutchison (since 2008)

CFO Thomas Rose (since 2002)

Return on Capital (Average, Past 3 Years)


Compound Annual Revenue Growth (Over Past 3 Years)



$20 million / $11 million

Other Highly Rated Medical Equipment Stocks

Medtronic (NYSE:MDT)

Intuitive Surgical (NASDAQ:ISRG)

CAPS Members Bullish on RTIX Also Bullish on

Johnson & Johnson (NYSE:JNJ)

General Electric (NYSE:GE)

CAPS Members Bearish on RTIX Also Bearish on (NASDAQ:BIDU)


Sources: Capital IQ (a division of Standard & Poor's) and Motley Fool CAPS.

On CAPS, 97% of the 74 All-Star members who have rated RTI Biologics believe the stock will outperform the S&P 500 going forward. These bulls include udflyerz, who is ranked in the top 10% of our community, and UltraLong, the second-ranked member in all of CAPS.

Two months ago, udflyerz informed Fools that RTI Biologics' recent marriage is beginning to bear fruit: "Merger with next door neighbor Tutogen now starting to pay off. Could be a baby [LifeCell] in the making."

In a pitch from just last week, UltraLong elaborates:

Revenue growth steady at 10-13% per annum, priced well below tangible assets (almost 1/2 of actual value), 10M more cash than debt and growing earnings (about 16 times 2010), with a technically oversold condition. Did I mention they are in my favorite sector? Medical devices and implants! There is nothing not to like here with [RTI Biologics] and I think it sees $5 again with ease.

What do you think about RTI Biologics, or any other stock for that matter? If you want to retire rich, you need to put together the best portfolio you can. Owning exceptional stocks is a surefire way to secure your financial future, and on Motley Fool CAPS, thousands of investors are working every day to find them. CAPS is 100% free, so get started!

Fool contributor Brian Pacampara doesn't own a position in any of the companies mentioned. Akamai, Intuitive Surgical, and Baidu are Motley Fool Rule Breakers picks and Johnson & Johnson is an Income Investor choice. Motley Fool Options has recommended a buy calls position on Johnson & Johnson. The Fool owns shares of and has written puts on Medtronic. The Fool's disclosure policy always gets a perfect score.